文献速递淋巴瘤

如何治疗早期复发性滤泡性淋巴瘤

How I treat early-relapsing follicular lymphoma.
PubMed 文献 · Blood · 2019-01-30

滤泡性淋巴瘤(FL)是最常见的惰性非霍奇金淋巴瘤,约20%的患者在化学免疫治疗后24个月内出现疾病进展(POD24),这与生存期差相关。目前尚无在诊断时识别POD24风险患者的标准方法,POD24患者也缺乏标准化治疗。本综述概述了早期复发性FL,并基于近期数据介绍了作者的患者管理方法。

要点

  • 约20%的滤泡性淋巴瘤患者在化学免疫治疗后24个月内出现疾病进展(POD24)。
  • POD24是生存期差的稳健标志,与死亡风险增加相关。
  • 目前尚无在诊断时识别POD24风险患者的标准方法,POD24治疗亦缺乏标准化方案。

核心结论

  • POD24是滤泡性淋巴瘤生存期差的稳健标志,与死亡风险增加相关,但目前尚无在诊断时识别POD24风险患者的标准方法,POD24治疗也缺乏标准化方案,相关研究正在进行中。

研究设计与样本

  • 综述,检索范围未在原文中明确报告。

主要发现

  • 滤泡性淋巴瘤是最常见的惰性非霍奇金淋巴瘤,临床病程可变,约20%的患者在化学免疫治疗后24个月内出现疾病进展(POD24)。
  • POD24是生存期差的稳健标志,与死亡风险增加相关。
  • 目前尚无在诊断时识别POD24风险患者的标准方法,但全球多项研究正在探索临床、病理和影像学生物标志物以帮助预测POD24。
  • POD24患者缺乏标准化治疗,但正在研究新型靶向治疗和自体干细胞移植策略。

临床怎么用

  • 作者基于近期可获数据介绍了对早期复发性滤泡性淋巴瘤患者的管理方法。

局限性

  • 目前尚无在诊断时识别POD24风险患者的标准方法。
  • POD24患者缺乏标准化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma, with generally favorable outcomes but a variable clinical course. Recent studies have elucidated the consistent and reproducible frequency of early disease progression in FL, occurring in ∼20% of patients. Relapse of FL within 24 months of chemoimmunotherapy (POD24) is now established as a robust marker of poor survival, leading to increased risk of death. Currently, there is no established method of identifying patients at risk for early disease progression at the time of their FL diagnosis. However, numerous studies worldwide are investigating clinical, pathologic, and radiographic biomarkers to help predict POD24, thereby improving subsequent outcomes and adapting therapy based on individual risk. There is also a paucity of standardized treatments for patients with POD24, but investigations are ongoing testing novel targeted therapies and autologous stem cell transplantation strategies. This review provides an overview of early-relapsing FL and our approach to patient management based on recent available data.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Casulo C, Barr PM. How I treat early-relapsing follicular lymphoma. Blood. 2019. PMID: 30700421. doi:10.1182/blood-2018-08-822148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。